Utilizing the Immune Response to Tumor Neoantigens for Kidney Cancer Early Detection
Abstract
Advanced-stage renal cell carcinoma (RCC) results in markedly reduced survival compared to curable early-stage RCC, which highlights the need for better cure rates through early detection. Screening assays are needed that allow for detecting all RCC at stage I. Here, we tested the hypothesis that immune response to clear cell RCC (ccRCC) neoantigens provides a signal of stage I ccRCC in blood. Using the Serum Epitope Repertoire Analysis (SERA) platform, which utilizes a library of peptides that are displayed on bar-coded bacteria to identify antibodies that are present in serum, we profiled the antibody repertoire in 177 ccRCC patients across stages and grades and compare these to 23 patients with benign kidney lesions and to 1519 non-cancer controls. We found that ccRCC patients have a richer antibody repertoire. However, each epitope is shared only in up to approx. 10 percent of ccRCC patients. Additionally, many antibodies that are enriched in ccRCC patients correspond to epitopes that do not map to the linear human proteome. Further work is needed to reveal the nature of these epitopes and to develop methods for 'binning' enriched epitopes in RCC, e.g., on the protein level, to reveal common antigenic proteins and pathways in ccRCC.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2022
- Accession Number
- AD1191172
Entities
People
- Alice C. Fan
Organizations
- Stanford University